SQSTM1/P62-targeted small molecules for multiple myeloma disease

Ended Project Grant Awarded Last action

Award ID
R44CA210882
Recipient
Awarding agency
Obligated
$2,307,561

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date
Originally
Funding
  • $2,307,295.89 Federal
  • $265.59 Non-federal
Place of performance
Pennsylvania, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment -$1 $0
Amendment -$340 $0
Amendment $266 $0
Amendment $266 $266
Amendment $266 $0
Amendment -$340 $0
Amendment $340 $0
Amendment -$340 -$340
Amendment $340 $340
Amendment -$340 $0
Amendment SQSTM1/P62-targeted small molecules for multiple myeloma disease - despite the introduction of new anti-multiple myeloma (MM) treatment regimens, such as… $340 $0
Amendment $1,000,000 $0
Amendment $0 $0
Amendment $1,000,000 $0
Amendment $0 $0
Amendment $0 $0
Amendment $6,840 $0
Original award $300,000 $0
Show all 18

Quick answers

Who received award R44CA210882?

R44CA210882 was awarded to Id4Pharma LLC by National Cancer Institute (National Institutes of Health) on May 23, 2017.

How much is award R44CA210882 worth?

$2,307,561 has been obligated on R44CA210882: $2,307,296 in federal funding and $266 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award